ChemDiv and Carna Collaborate to Develop and Market Annotated Kinase Focused Library
News Mar 31, 2006
ChemDiv, Inc. and Carna Biosciences, Inc. have announced the signing of a collaboration agreement to form a partnership to develop and market annotated kinase focused libraries targeting kinases for various pathways and disease.
ChemDiv's proprietary chemistry is designed to permit small molecule drug development for such kinases while Carna's expertise in kinase assay development and profiling provides rapid screening results for an added annotated component to ChemDiv's kinase libraries.
"We are very excited about the possibility of rapidly targeting kinase proteins, that have been known to be involved in cancer and other serious diseases, as the focus of our collaboration," said Nikolay Savchuk, President & CEO of ChemDiv, Inc.
"Carna is able to expand our kinase focused products and services by forming the strategic alliance with ChemDiv," said Kohichiro Yoshino, President of Carna.
"Our proprietary technologies and know-how on assay development and screening and ChemDiv's proprietary technologies on kinase focused library development are so complementary that I am confident in the outcome of this collaboration."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE